Genetic counselors are trying once again to gain Medicare recognition through this bill, so they can bill for their services.

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.

With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.

The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.

The startup aims to create a platform for treating extremely rare genetic mutations, armed with CRISPR advances and new regulatory pathways.

NEW YORK – Mdxhealth and the University of Oxford will test whether the firm's Genomic Prostate Score (GPS) assay can predict disease progression and treatment outcomes in prostate cancer patients, ...

NEW YORK – Cartography Biosciences said on Tuesday it will collaborate with Pfizer to use its drug discovery platforms to identify tumor-selective antigens for an undisclosed cancer indication. Under ...